Negative dimension in psychiatry. Amotivational syndrome as a paradigm of negative symptoms in substance abuse

Rivista di Psichiatria

Volumn 48, Issue 1, 2013, Pages 1-9

  Rovai, Luca ^a   Maremmani, Angelo Giovanni Icro ^a,b   Pacini, Matteo ^b   Pani, Pier Paolo ^d   Rugani, Fabio ^a   Lamanna, Francesco ^b,c   Schiavi, Elisa ^a   Mautone, Salvatore ^a,d   Dell'Osso, Liliana ^a   Maremmani, Icro ^a,b  

^a UNIVERSITY OF PISA   (Italy)

^b G DE LISIO INSTITUTE OF BEHAVIOURAL SCIENCES   (Italy)

^c SerT (Drug Addiction Unit)   (Italy)

^d Addiction Treatment Unit (SerT)   (Italy)

Author keywords

Amotivational syndrome; Hypophoria; Negative symptoms; Reward deficiency syndrome

Indexed keywords

CENTRAL STIMULANT AGENT;

ADDICTION; AMOTIVATIONAL SYNDROME; ARTICLE; CANNABIS ADDICTION; HEROIN DEPENDENCE; HUMAN; MENTAL DISEASE; MOOD DISORDER; NEGATIVE SYNDROME; PLEIOTROPY; POST WITHDRAWAL SYNDROME; PSYCHIATRY; REWARD DEFICIENCY SYNDROME; SCHIZOPHRENIA; SEXUAL AROUSAL DISORDER; SUBSTANCE ABUSE; WITHDRAWAL SYNDROME; MOTIVATION; PSYCHOLOGICAL ASPECT; REVIEW; SYNDROME;

HUMANS; MENTAL DISORDERS; MOTIVATION; SUBSTANCE-RELATED DISORDERS; SYNDROME;

MLCS; MLOWN;

EID: 84875590711     PISSN: 00356484     EISSN: 20382502     Source Type: Journal    
DOI: None     Document Type: Article

References (117)

1. Hafner H, Loffler W, Maurer K, Hambrecht M, an der Heiden W. Depression, negative symptoms, social stagnation and social decline in the early course of schizophrenia. Acta Psychiatr Scand 1999; 100: 105-18.
2. Milak MS, Aniskin DB, Eisenberg DP, et al. The negative syndrome as a dimension: factor analyses of PANSS in major depressive disorder and organic brain disease compared with negative syndrome structures found in the schizophrenia literature. Cogn Behav Neurol 2007; 20: 113-20.
3. Winograd-Gurvich C, Fitzgerald PB, Georgiou-Karistianis N, Bradshaw JL, White OB. Negative symptoms: a review of schizophrenia, melancholic depression and Parkinson's disease. Brain Res Bull 2006; 70: 312-21.
4. Tamminga CA, Buchanan RW, Gold JM. The role of negative symptoms and cognitive dysfunction in schizophrenia outcome. Int Clin Psychopharmacol 1998; 13 Suppl 3: S21-6.
5. O'Leary DS, Flaum M, Kesler ML, Flashman LA, Arndt S, Andreasen NC. Cognitive correlates of the negative, disorganized, and psychotic symptom dimensions of schizophrenia. J Neuropsychiatry Clin Neurosci 2000; 12: 4-15.
6. Sax KW, Strakowski SM, Keck PE Jr., Upadhyaya VH, West SA, McElroy SL. Relationships among negative, positive, and depressive symptoms in schizophrenia and psychotic depression. Br J Psychiatry 1996; 168: 68-71.
7. Gerbaldo H, Fickinger MP, Wetzel H, Helisch A, Philipp M, Benkert O. Primary enduring negative symptoms in schizophrenia and major depression. J Psychiatr Res 1995; 29: 297-302.
8. Toomey R, Faraone SV, Simpson JC, Tsuang MT. Negative, positive, and disorganized symptom dimensions in schizophrenia, major depression, and bipolar disorder. J Nerv Ment Dis 1998; 186: 470-6.
9. Maziade M, Roy MA, Martinez M, et al. Negative, psychoticism, and disorganized dimensions in patients with familial schizophrenia or bipolar disorder: continuity and discontinuity between the major psychoses. Am J Psychiatry 1995; 152: 1458-63.
10. Lewine RR. A discriminant validity study of negative symptoms with a special focus on depression and antipsychotic medication. Am J Psychiatry 1990; 147: 1463-6.
11. Chaturvedi SK, Sarmukaddam SB. Prediction of outcome in depression by negative symptoms. Acta Psychiatr Scand 1986; 74: 183-6.
12. Bonanno GA, Neria Y, Mancini A, Coifman KG, Litz B, Insel B. Is there more to complicated grief than depression and posttraumatic stress disorder? A test of incremental validity. J Abnorm Psychol 2007; 116: 342-51.
13. Shear K, Shair H. Attachment, loss, and complicated grief. Dev Psychobiol 2005; 47: 253-67.
14. Shear K, Monk T, Houck P, et al. An attachment-based model of complicated grief including the role of avoidance. Eur Arch Psychiatry Clin Neurosci 2007; 257: 453-61.
15. Stroebe M, Boelen PA, van den Hout M, Stroebe W, Salemink E, van den Bout J. Ruminative coping as avoidance: a reinterpretation of its function in adjustment to bereavement. Eur Arch Psychiatry Clin Neurosci 2007; 257: 462-72.
16. Prigerson HG, Frank E, Kasl SV, et al. Complicated grief and bereavement-related depression as distinct disorders: preliminary empirical validation in elderly bereaved spouses. Am J Psychiatry 1995; 152: 22-30.
17. Boelen PA, Huntjens RJ, van Deursen DS, van den Hout MA. Autobiographical memory specificity and symptoms of complicated grief, depression, and posttraumatic stress disorder following loss. J Behav Ther Exp Psychiatry 2010; 41: 331-7.
18. Olley A, Malhi G, Sachdev P. Memory and executive functioning in obsessive-compulsive disorder: a selective review. J Affect Disord 2007; 104: 15-23.
19. Kuelz AK, Hohagen F, Voderholzer U. Neuropsychological performance in obsessive-compulsive disorder: a critical review. Biol Psychol 2004; 65: 185-236.
20. Martin WR. Pathophysiology of narcotic addiction: possible role of protracted abstinence in relapse. In: Zarafonetis CJD (ed). Drug abuse. Philadelphia: Lea and Febiger, 1972.
21. Martin WR, Hewett BB, Baken AJ, Heartzen CA. Aspects of the psychopathology and pathophysiology of addiction. Drug Alcohol Depend 1977; 2: 185-202.
22. Martin J, Ingles J. Pain tolerance and narcotic addiction. Br J Soc Psychol 1965; 4: 224-9.
23. Blum K, Braverman ER, Holder JM, et al. Reward deficiency syndrome: a biogenetic model for the diagnosis and treatment of impulsive, addictive, and compulsive behaviors. J Psychoactive Drugs 2000; 32: 1-112.
24. Lynskey M, Hall W. The effects of adolescent cannabis use on educational attainment: a review. Addiction 2000; 95: 1621-30.
25. French ED, Dillon K, Wu X. Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra. Neuroreport 1997; 8: 649-52.
26. Gardner EL, Vorel SR. Cannabinoid transmission and rewardrelated events. Neurobiol Dis 1998; 5: 502-33.
27. Tanda G, Goldberg SR. Cannabinoids: reward, dependence, and underlying neurochemical mechanisms. A review of recent preclinical data. Psychopharmacology (Berl) 2003; 169: 115-34.
28. Bossong MG, van Berckel BN, Boellaard R, et al. Delta 9-tetrahydrocannabinol induces dopamine release in the human striatum. Neuropsychopharmacology 2009; 34: 759-66.
29. Filbey FM, Schacht JP, Myers US, Chavez RS, Hutchison KE. Marijuana craving in the brain. Proc Natl Acad Sci U S A 2009; 106: 13016-21.
30. Devane WA, Dysarz FA 3rd, Johnson MR, Melvin LS, Howlett AC. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988; 34: 605-13.
31. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365: 61-5.
32. Gardner EL. Addictive potential of cannabinoids: the underlying neurobiology. Chem Phys Lipids 2002; 121: 267-90.
33. Wise RA. Neurobiology of addiction. Curr Opin Neurobiol 1996; 6: 243-51.
34. van Hell HH, Vink M, Ossewaarde L, Jager G, Kahn RS, Ramsey NF. Chronic effects of cannabis use on the human reward system: an fMRI study. Eur Neuropsychopharmacol 2010; 20: 153-63.
35. Howlett AC, Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, Porrino LJ. Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology 2004; 47 Suppl 1: 345-58.
36. Sim-Selley LJ. Regulation of cannabinoid CB1 receptors in the central nervous system by chronic cannabinoids. Crit Rev Neurobiol 2003; 15: 91-119.
37. Bovasso GB. Cannabis abuse as a risk factor for depressive symptoms. Am J Psychiatry 2001; 158: 2033-7.
38. Janiri L, Martinotti G, Dario T, et al. Anhedonia and substancerelated symptoms in detoxified substance-dependent subjects: a correlation study. Neuropsychobiology 2005; 52: 37-44.
39. Tanda G, Pontieri FE, Di Chiara G. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common m1 opioid receptor mechanism. Science 1997; 276: 2048-50.
40. Tanda G, Loddo P, Di Chiara G. Dependence of mesolimbic dopamine transmission on delta9-tetrahydrocannabinol. Eur J Pharmacol 1999; 376: 23-6.
41. Ledent C, Valverde O, Cossu G, et al. Unresponsiveness to cannabinoid and reduced addictive effects of opiates in CBI receptor knockout mice. Science 1999; 283: 401-4.
42. Navarro M, Carrera MR, Fratta W, et al. Functional interaction between opioid and cannabinoid receptors in drug self-administration. J Neurosci 2001; 21: 5344-50.
43. Zimmer A, Valjent E, Konig M, et al. Absence of delta -9-tetrahydrocannabinol dysphoric effects in dynorphin-deficient mice. J Neurosci 2001; 21: 9499-505.
44. Ghozland S, Matthes HW, Simonin F, Filliol D, Kieffer BL, Maldonado R. Motivational effects of cannabinoids are mediated by mu-opioid and kappa-opioid receptors. J Neurosci 2002; 22: 1146-54.
45. Maremmani I, Castrogiovanni P. Disturbi da uso di sostanze. Disturbi da oppiacei ed analgesici. In: Cassano GB, et al. (eds). Trattato Italiano di Psichiatria. Volume 2 (43). Milano: Masson, 1992.
46. Maremmani I, Pacini M. Understanding the pathogenesis of drug addiction in order to implement a correct pharmacological intervention. Heroin Addict Relat Clin Probl 2003; 5: 5-12.
47. Akiskal HS, Judd LL, Gillin JC, Lemmi H. Subthreshold depressions: clinical and polysomnographic validation of dysthymic, residual and masked forms. J Affect Disord 1997; 45: 53-63.
48. Bozarth MA, Wise R. Heroin reward is dependent on a dopaminergic substrate. Life Sci 1981; 29: 1881-6.
49. Karler R, Calder L, Thai L, Bedingfield B. A dopaminergic-glutamatergic basis for the action of amphetamine and cocine Brain Res 1994; 658: 8-14.
50. Roberts DC, Ranaldi R. Effect of dopaminergic drugs on cocaine reinforcement. Clin Neuropharmacol. 1995; 18: S84-S95.
51. Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 1988; 85: 5274-378.
52. Pontieri FE, Tanda G, Di Chiara G. Intravenous cocaine, morphine, and amphetamine preferentially increase extracellular dopamine in the "shell" as compared with the "core" of the rat nucleus accumbens. Proc Natl Acad Sci USA 1995; 92: 12304-8.
53. Drevets WC, Gautier C, Price JC, et al. Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria. Biol Psychiatry 2001; 49: 81-96.
54. Kelley AE, Berridge KC. The neuroscience of natural rewards: relevance to addictive drugs. J Neurosci 2002; 22: 3306-11.
55. Berridge KC. The debate over dopamine's role in reward: the case for incentive salience. Psychopharmacology (Berl) 2007; 191: 391-431.
56. Hyman SE. Addiction: a disease of learning and memory. Am J Psychiatry 2005; 162: 1414-22.
57. Kalivas PW, Volkow ND. The neural basis of addiction: a pathology of motivation and choice. Am J Psychiatry 2005; 162: 1403-13.
58. Pierce RC, Kalivas PW. A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants. Brain Res 1997; 25: 192-216.
59. Robinson TE, Berridge KC. Incentive-sensitization and addiction. Addiction 2001; 96: 103-14.
60. Carlezon WA, Nestler EJ. Elevated levels of GluR1 in the midbrain: a trigger for sensitization to drugs of abuse? Trends Neurosci 2002; 25: 610-5.
61. Vezina P. Sensitization of midbrain dopamine neuron reactivity and the self-administration of psychomotor stimulant drugs. Neurosci Biobehav Rev 2004; 27: 827-39.
62. Nestler EJ. Common molecular and cellular substrates of addiction and memory. Neurobiol Learn Mem 2002; 78: 637-47.
63. Bolaños CA, Nestler EJ. Neurotrophic mechanisms in drug addiction. Neuromolecular Med 2004; 5: 69-83.
64. Carlezon WA, Konradi C. Understanding the neurobiological consequences of early exposure to psychotropic drugs: linking behavior with molecules. Neuropharmacology 2004; 47: 47-60.
65. Volkow ND, Fowler JS, Wang GJ, Goldstein RZ. Role of dopamine, the frontal cortex and memory circuits in drug addiction: insight from imaging studies. Neurobiol Learn Mem 2002; 78: 610-24.
66. Robbins TW, Everitt BJ. Limbic-striatal memory systems and drug addiction. Neurobiol Learn Mem 2002; 8: 625-36.
67. Childress AR, Mozley PD, McElgin W, Fitzgerald J, Reivich M, O'Brien CP. Limbic activation during cue-induced cocaine craving. Am J Psychiatry 1999; 156: 11-8.
68. Garavan H, Pankiewicz J, Bloom A, et al. Cue-induced cocaine craving: neuroanatomical specificity for drug users and drug stimuli Am J Psychiatry 2000; 157: 1789-98.
69. Wexler BE, Gottschalk CH, Fulbright RK, et al. Functional magnetic resonance imaging of cocaine craving. Am J Psychiatry 2001; 158: 86-95.
70. Wang GJ, Volkow ND, Fowler JS, et al. Regional brain metabolic activation during craving elicited by recall of previous drug experiences. Life Sci 1999; 64: 775-84.
71. Grant S, London ED, Newlin DB, et al. Activation of memory circuits during cue-elicited cocaine craving. Proc Natl Acad Sci U S A 1996; 93: 12040-5.
72. Maas LC, Lukas SE, Kaufman MJ, et al. Functional magnetic resonance imaging of human brain activation during cue-induced cocaine craving. Am J Psychiatry 1998; 155: 124-6.
73. Volkow ND, Fowler JS, Wolf AP, et al. Changes in brain glucose metabolism in cocaine dependence and withdrawal. Am J Psychiatry 1991; 148: 621-6.
74. Breiter HC, Gollub RL, Weisskoff RM, et al. Acute effects of cocaine on human brain activity and emotion. Neuron 1997; 19: 591-611.
75. Volkow ND, Wang GJ, Fowler JS, et al. Association of methylphenidate- induced craving with changes in right striatoorbitofrontal metabolism in cocaine abusers: implications in addiction. Am J Psychiatry 1999; 156: 19-26.
76. Volkow ND, Wang GJ, Ma Y, et al. Expectation enhances the regional brain metabolic and the reinforcing effects of stimulants in cocaine abusers. J Neurosci 2003; 23: 11461-8.
77. Volkow ND, Hitzemann R, Wang GJ, et al. Long-term frontal brain metabolic changes in cocaine abusers. Synapse 1992; 11: 184-90.
78. Volkow ND, Hitzemann R, Wang GJ, et al. Decreased brain metabolism in neurologically intact healthy alcoholics. Am J Psychiatry 1992; 149: 1016-22.
79. Volkow ND, Wang GJ, Hitzemann R, et al. Recovery of brain glucose metabolism in detoxified alcoholics. Am J Psychiatry 1994; 151: 178-83.
80. Volkow ND, Wang GJ, Overall JE, et al. Regional brain metabolic response to lorazepam in alcoholics during early and late alcohol detoxification. Alcohol Clin Exp Res 1997; 21: 1278-84.
81. Catafau AM, Etcheberrigaray A, Perez de los Cobos J, et al. Regional cerebral blood flow changes in chronic alcoholic patients induced by naltrexone challenge during detoxification. J Nucl Med 1999; 40: 19-24.
82. Kaufman JN, Ross TJ, Stein EA, Garavan H. Cingulate hypoactivity in cocaine users during a GO-NOGO task as revealed by event-related functional magnetic resonance imaging. J Neurosci 2003; 23: 7839-43.
83. Forman SD, Dougherty GG, Casey BJ, et al. Opiate addicts lack error-dependent activation of rostral anterior cingulate Biol Psychiatry 2004; 55: 531-7.
84. Volkow ND, Fowler JS, Wolf AP, et al. Effects of chronic cocaine abuse on postsynaptic dopamine receptors. Am J Psychiatry 1990; 147: 719-24.
85. Volkow ND, Fowler JS, Wang GJ, et al. Decreased dopamine D2 receptor availability is associated with reduced frontal metabolism in cocaine abusers. Synapse 1993; 14: 169-77.
86. Wang GJ, Volkow ND, Fowler JS, et al. Dopamine D2 receptor availability in opiate-dependent subjects before and after naloxone-precipitated withdrawal. Neuropsychopharmacology 1997; 16: 174-82.
87. Volkow ND, Chang L, Wang GJ, et al. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry 2001; 158: 377-82.
88. Volkow ND, Wang GJ, Telang F, et al. Profound decreases in dopamine release in striatum in detoxified alcoholics: possible orbitofrontal involvement. J Neurosci 2007; 27: 12700-6.
89. Piazza PV, Le Moal M. The role of stress in drug self-administration. Trends Pharmacol Sci 1998; 19: 67-74.
90. Goeders NE. The impact of stress on addiction. Eur Neuropsychopharmacol 2003; 13: 435-41.
91. Richter R, Weiss F. In vivo CRF release in rat amygdala is increased during cocaine withdrawal in self-administration rats. Synapse 1999; 32: 254-61.
92. Sarnyai Z, Shaham Y, Heinrichs SC. The role of corticotropinreleasing factor in drug addiction. Pharmacol Rev 2001; 53: 209-43.
93. Weiss F, Ciccocioppo R, Parsons LH, et al. Compulsive drugseeking behavior and relapse. Neuroadaptation, stress, and conditioning factors. Ann NY Acad Sci 2001; 937: 1-26.
94. Maj M, Turchan J, Smialowska M, Przewlocka B. Morphine and cocaine influence on CRF biosynthesis in the rat central nucleus of amygdala. Neuropeptides 2003; 37: 105-10.
95. Cador M, Cole BJ, Koob GF, Stinus L, Le Moal M. Central administration of corticotropin releasing factor induces long-term sensitization to d-amphetamine. Brain Res 1993; 606: 181-6.
96. Stam R, Bruijnzeel AW, Wiegant VM. Long-lasting stress sensitisation. Eur J Pharmacol 2000; 405: 217-24.
97. Merlo Pich E, Lorang M, Yeganeh M, et al. Increase of extracellular corticotrophin releasing factor-like immunoreactivity levels in the amygdala of awake rats during restraint stress and ethanol withdrawal as measured by microdialysis. J Neurosci 1995; 15: 5439-47.
98. Koob GF. Stress, corticotropin-releasing factor, and drug addiction. Ann NY Acad Sci 1999; 897: 27-45.
99. Koob GF. Neuroadaptive mechanisms of addiction: studies on the extended amygdala. Eur Neuropsychopharmacol 2003; 13: 442-52.
100. Prado-Alcala R, Wise RA. Brain stimulation reward and dopamine terminal fields. I. Caudate-putamen, nucleus accumbens and amygdala. Brain Res 1984; 297: 265-73.
101. Imperato A, Di Chiara G. Preferential stimulation of dopamine release in the nucleus accumbens of freely-moving rats by ethanol. J Pharmacol Exp Ther 1986; 239: 219-38.
102. Damsma G, Day J, Fibiger HC. Lack of tolerance to nicotineinduced dopamine release in the nucleus accumbens. Eur J Pharmacol 1989; 168: 363-8.
103. Kuczenski R, Segal DS, Aizenstein ML. Amphetamine, cocaine, and fencamfamine: relationship between locomotor and stereotypy response profiles and caudate and accumbens dopamine dynamics. J Neurosci 1991; 11: 2703-12.
104. Chang JY, Sawyer SF, Lee RS, Woodward DJ. Electrophysiological and pharmacological evidence for the role of the nucleus accumbens in cocaine self-administration in freely moving rats. J Neurosci 1994; 14: 1224-44.
105. Pontieri FE, Tanda G, Orzi F, Di Chiara G. Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature 1996; 382: 255-7.
106. Benwell ME, Balfour DJ. The effects of acute and repeated nicotine treatment on nucleus accumbens dopamine and locomotor activity. Br J Pharmacol 1992; 105: 849-56.
107. Perez MF, Ford KA, Goussakov I, Stutzmann GE, Hu XT. Repeated cocaine exposure decreases dopamine D(2)-Like receptor modulation of Ca(2+) homeostasis in rat nucleus accumbens neurons. Synapse 2011; 65: 168-80.
108. Bowirrat A, Oscar-Berman M. Relationship between dopaminergic neurotransmission, alcoholism, and reward deficiency syndrome. Am J Med Genet B Neuropsychiatr Genet 2005; 132B: 29-37.
109. Blum K, Noble EP. Allelic association of human dopamine D2 receptor gene in alcoholism. JAMA 1994; 263: 2055-60.
110. Blum K, Wood RC, Braverman ER, Chen TJ, Sheridan PJ. The D2 dopamine receptor gene as a predictor of compulsive disease: Bayes' theorem. Funct Neurol 1995; 10: 37-44.
111. Khantzian EJ. The self-medicatio hypothesis of addictive disorders: focus on heroin and cocaine dependence. Am J Psychiatry 1985; 142: 1259-64.
112. Crunelle CL, Miller ML, Booij J, van den Brink W. The nicotinic acetylcholine receptor partial agonist varenicline and the treatment of drug dependence: a review. Eur Neuropsychopharmacol 2010; 20: 69-79.
113. Palmatier MI, Levin ME, Mays KL, Donny EC, Caggiula AR, Sved AF. Bupropion and nicotine enhance responding for nondrug reinforcers via dissociable pharmacological mechanisms in rats. Psychopharmacology (Berl) 2009; 207: 381-90.
114. Grieder TE, Sellings LH, Vargas-Perez H, et al. Dopaminergic signaling mediates the motivational response underlying the opponent process to chronic but not acute nicotine. Neuropsychopharmacology 2010; 35: 943-54.
115. Danna CL, Elmer GI. Disruption of conditioned reward association by typical and atypical antipsychotics. Pharmacol Biochem Behav 2010; 96: 40-7.
116. Kapur S, Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry 2001; 158: 360-9.
117. Campbell I. The amotivational syndrome and cannabis use with emphasis on the Canadian scene. Ann NY Acad Sci 1976; 282: 33-6.